Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Ionis Pharmaceuticals

This page shows the latest Ionis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to

Latest news

  • Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

    FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... However Ionis faces stiff competition from

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    Alnylam's success in the phase III trial proved to be a dampener for Ionis Pharmaceuticals, which is developing antisense-based drug inotersen for this type of familial amyloid polyneuropathy (FAP). ... The company shares fell yesterday on the APOLLO

  • Safety issues dampen enthusiasm for Akcea's volanesorsen Safety issues dampen enthusiasm for Akcea's volanesorsen

    But Ionis Pharmaceuticals' subsidiary presses on with filing plans. Akcea Therapeutics says it plans to file for approval of its drug for rare disease familial chylomicronaemia syndrome (FCS) later this year ... There was also a reduction in pancreatitis

  • Merck & Co wins hepatitis C patent dispute with Gilead Merck & Co wins hepatitis C patent dispute with Gilead

    The jury in the lawsuit upheld Merck's claim that Gilead's sofosbuvir - which features in its massive-selling Sovaldi and Harvoni HCV drugs - infringes two patents it holds alongside Ionis ... Pharmaceuticals (formerly known as Isis Pharma).

  • Isis renamed Ionis to sidestep militant association Isis renamed Ionis to sidestep militant association

    Says the move should avoid any 'distraction' to its business. Isis has announced a change in name to Ionis Pharmaceuticals in a bid to avoid any association with the Islamic State ... Ionis "is an original name that the company has chosen to represent

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in ... Meanwhile, Karuna Pharmaceuticals has raised $42m to resurrect

  • Deal Watch October 2018

    Tregs) while preserving effector T‐cells (Teffs). Acquisition. $759m. Ionis Pharmaceuticals/. Roche. ... US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal.

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis Pharmaceuticals and Bayer entered into a licence in May 2015 for IONIS-FXIRx, an antisense therapeutic designed to reduce the production of Factor XI for the prevention of thrombosis. ... Licence, collaboration. 237.5. Portola

  • Deal Watch May 2016 Deal Watch May 2016

    This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia